You are here

Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease.

Evaluation of the Quality of Semen and Sexual Function in Men with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 May 16;: Authors: Valer P, Algaba A, Santos D, Fuentes ME, Nieto E, Gisbert JP, López P, Quintanilla E, García-Alonso FJ, Guerra I, Páez Á, Bermejo F Abstract BACKGROUND: Data on fertility rates and medication safety in men with inflammatory bowel disease (IBD) are limited. The aim of this study was to evaluate whether there is a seminal alteration in patients with IBD and, if so, to evaluate the mechanisms that…

Read More

Complementary Roles of Nod2 in Hematopoietic and Nonhematopoietic Cells in Preventing Gut Barrier Dysfunction Dependent on MLCK Activity.

Complementary Roles of Nod2 in Hematopoietic and Nonhematopoietic Cells in Preventing Gut Barrier Dysfunction Dependent on MLCK Activity. Inflamm Bowel Dis. 2017 May 16;: Authors: Al Nabhani Z, Montcuquet N, Roy M, Dussaillant M, Hugot JP, Barreau F Abstract BACKGROUND: Crohn’s disease (CD) pathogenesis is multifactorial involving genetic and environmental factors. Loss of function mutations in the nucleotide oligomerization domain 2 (NOD2) gene are the main genetic risk factor for CD. Like patients with CD, Nod2 mice are characterized by an enhanced Th1 immune response and a defective mucosal barrier…

Read More

Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis.

Clinical Course of Ulcerative Colitis After Liver Transplantation in Patients with Concomitant Primary Sclerosing Cholangitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017 May 16;: Authors: Fattahi MR, Malek-Hosseini SA, Sivandzadeh GR, Safarpour AR, Bagheri Lankarani K, Taghavi AR, Ejtehadi F Abstract BACKGROUND: The natural history of ulcerative colitis (UC) after liver transplantation (LT) for primary sclerosing cholangitis (PSC) remains ill defined. This study aimed to evaluate the course of UC after LT for PSC. METHODS: The course of UC, including the clinical colitis severity index, was evaluated in patients with…

Read More

Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease.

Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 May 16;: Authors: Borren NZ, Conway G, Tan W, Andrews E, Garber JJ, Yajnik V, Ananthakrishnan AN Abstract BACKGROUND: Optimal treatment of inflammatory bowel disease (IBD) requires specialized health care. Patients frequently travel long distances to obtain care for IBD, which may hinder regular care and affect outcomes adversely. METHODS: This study included patients with established Crohn’s disease or ulcerative colitis receiving care at a single referral center between January 2005 and August 2016. Distance…

Read More

Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease.

Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jun;23(6):858-865 Authors: Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY Abstract BACKGROUND AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical costs….

Read More

Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.

Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jun;23(6):853-857 Authors: Yadav A, Foromera J, Feuerstein I, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn’s disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners report…

Read More

Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease.

Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 May 15;: Authors: Nguyen GC, Boland K, Afif W, Bressler B, Jones JL, Weizman AV, Fowler S, Halder S, Huang VW, Kaplan GG, Khanna R, Murthy SK, Ruel J, Seow CH, Targownik LE, Chawla T, Guimaraes L, Fernandes A, Saleh S, Melmed GY Abstract BACKGROUND AND AIMS: The prevalence and incidence of inflammatory bowel disease (IBD) in North America is among the highest in the world and imparts substantial direct and indirect medical…

Read More

Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease.

Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 May 15;: Authors: Yadav A, Foromera J, Feuerstein I, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) has developed guidelines for the management of ulcerative colitis and Crohn’s disease (CD) recommending anti-TNF therapy in moderate-severe disease. However, which drug is used is often dictated by insurance company policies. We sought to determine the insurance policy requirements prior to approval of biologic therapies. METHODS: Using the National Association of Insurance Commissioners…

Read More

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Jun;23(6):998-1003 Authors: Glassner K, Malaty HM, Abraham BP Abstract BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has been increasingly identified in patients with inflammatory bowel disease (IBD). We aimed to determine risk factors of NAFLD in patients with IBD. METHODS: We examined 3 groups of patients: IBD + NAFLD, IBD only, and NAFLD only. Data on demographics, body mass index, duration of IBD, type of medication use, laboratory data, and metabolic risk…

Read More

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017 Jun;23(6):894-902 Authors: Heida A, Park KT, van Rheenen PF Abstract BACKGROUND: In asymptomatic patients with inflammatory bowel disease (IBD), “monitoring” involves repeated testing aimed at early recognition of disease exacerbation. We aimed to determine the usefulness of repeated fecal calprotectin (FC) measurements to predict IBD relapses by a systematic literature review. METHODS: An electronic search was performed in Medline, Embase, and Cochrane from inception to April 2016….

Read More
<< Go Back